Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

August 01, 1998; 51 (2) Brief Communications

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

G. D. Borasio, W. Robberecht, P. N. Leigh, J. Emile, R. J. Guiloff, F. Jerusalem, V. Silani, P. E. Vos, J.H.J. Wokke, T. Dobbins, European ALS/IGF-I Study Group*
First published August 1, 1998, DOI: https://doi.org/10.1212/WNL.51.2.583
G. D. Borasio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Robberecht
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. N. Leigh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Emile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. J. Guiloff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Jerusalem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Silani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. E. Vos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.H.J. Wokke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Dobbins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
G. D. Borasio, W. Robberecht, P. N. Leigh, J. Emile, R. J. Guiloff, F. Jerusalem, V. Silani, P. E. Vos, J.H.J. Wokke, T. Dobbins, European ALS/IGF-I Study Group*
Neurology Aug 1998, 51 (2) 583-586; DOI: 10.1212/WNL.51.2.583

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
84

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.

No satisfactory treatment is available for ALS. Insulin-like growth factor I (IGF-I), a pleiotropic polypeptide (molecular weight, 7.6 kd), has been shown to exert a trophic effect on motor neurons in vitro and in vivo.1 Phase 1 clinical studies with recombinant human IGF-I (rhIGF-I) shows good tolerability for subcutaneous administration.2 The goal of this study was to determine whether rhIGF-I could slow the progression of ALS as measured by the Appel ALS rating scale (AALS).

Methods. Patients who were 20 years of age or older with a clinical diagnosis of probable or definite sporadic ALS (according to the El Escorial criteria of the World Federation of Neurology) were eligible for screening at eight European centers (see *appendix*). Inclusion/exclusion criteria, screening period, and randomization criteria were identical to those of the recently published North American trial.3

The primary efficacy measure was the AALS total score.4 The AALS includes assessments of bulbar and respiratory function, upper and lower extremity function, and muscle strength. The total score ranges from 30 points (normal subject) to 164 points (maximal dysfunction). A secondary endpoint was the Sickness Impact Profile (SIP), a health-related quality of life measure.5 All patients were evaluate as baseline and monthly for up to 9 months for the AALS score. The SIP was assessed by independent interviewers at baseline and then every 3 months.

Patients were randomized in groups of six, stratified by center. Within each group, four patients received rhIGF-I (0.05 mg/kg) and two patients received placebo (indistinguishable vehicle in identical vials) on a double-blind basis as twice daily subcutaneous injections. This regimen achieved blood level similar to those effective in the animal models.6 The monthly average serum trough level (mean± SEM) of IGF-I was 580 ± 220 ng/mL in the active treatment group and 170 ± 70 ng/mL in the placebo treatment group.

If patients reached an AALS total score of >115, or a forced vital capacity (FVC) of <39% of the predicted value, they were withdrawn from the double-blind study and were offered open-label medication. Patients who completed the 9-month double-blind phase were also eligible for open-label medication. RhIGF-I (Myotrophin [mecasermin (recombinant DNA origin)] Injection) and placebo were supplied by Cephalon, Inc. (West Chester, PA).

The primary efficacy variable was the change in AALS total score from baseline to study endpoint (i.e., to the last available observed value) for each individual patient. Analyses of this variable included all patients receiving treatment with at least one postbaseline AALS assessment(n = 176). For patients who died or were discontinued before 9 months, their last available AALS total score was carried forward for all months subsequent to study termination, regardless of the reason (last observation carried forward [LOCF] method). An ANOVA model, adjusting for investigator and disease severity at baseline (low severity 40-60 AALS points, high severity >60 AALS points) was used. Treatment-by-investigator interaction was examined at a significance level of 0.1. The SIP was evaluated as change from baseline including all patients with at least one post-baseline assessment (n = 147). Data were expressed as mean± SEM, p values are two-tailed.

Results. Of 183 patients randomized (17 to 37/center), four were found in retrospect not to fulfill inclusion criteria at baseline (one patient with an FVC of 49.3%, three patients with insufficient progression during screening); these patients were included in the statistical analysis. Seven patients (six in the rhIGF-I group and one in the placebo group) were excluded from the analysis of the AALS change score because they did not have at least one postbaseline evaluation. For the most part, the treatment group characteristics at baseline were well balanced. (Details of the study demographic can be obtained from the National Auxiliary Publication Service [NAPS]; see note at end of article.) However, a retrospective survival analysis showed that a disproportionate number of patients at a higher death risk were randomized to the rhIGF-I group (see below). The AALS total score at baseline was 68.6 ± 1.8 for the placebo group, and 68.9± 1.3 for the rhIGF-I group. The patient enrollment and completion status is shown in the table.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table Enrollment and completion status

The mean change in AALS total score from baseline of the patients treated with rhIGF-I was 21.9 ± 1.5 versus 25.2 ± 2.3 for the placebo group (Δ = -3.3 points; 95%CI -8.7, 2.0; p = 0.22)(figure). No significant difference between treatment groups was found in the SIP scores (change from baseline: rhIGF-I, 9.4± 1.1; placebo, 10.5 ± 1.6; p = 0.59). The most frequent clinical adverse experiences were weakness, injection site pain, dyspnea, sweating, dysarthria, headache, and dysphagia. The incidence of adverse experiences was not significantly different between treatment groups.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure. Change from baseline of the Appel ALS rating scale (AALS) total score by month (mean ± SEM, last observation carried forward for all discontinued patients regardless of the reason for termination).

During the double-blind phase, 15% of the patients in the rhIGF-I group died, compared with 8% in the placebo group (p = 0.34, Fisher's exact test). All but two deaths were caused by respiratory failure. One patient committed suicide, and one patient with a history of colonic tumor resection and recurring ileus died of paralytic ileus. Both were in the rhIGF-I group. A detailed review of all deaths revealed no suspicion of hypoglycemia or cardiovascular events as the cause of death. A post hoc risk factor analysis showed a higher incidence of deaths in patients with FVC<80% or age ≥55 years at baseline. Both variables are known to correlate strongly with survival in ALS.7 The proportion of patients from the highest risk cohort (age ≥ 55 and FVC < 80%) randomized to the rhIGF-I group, compared with placebo, was almost 3:1, instead of the expected 2:1 ratio. Kaplan-Meier survival curves, when corrected for this imbalance, showed no difference between treatment groups.(Additional safety data and details of the risk factor analysis can be obtained from NAPS.)

Discussion. Although high expectations have been placed on the application of neurotrophic factors in neurodegenerative diseases, ciliary neurotrophic factor (CNTF)8,9 and brain-derived neurotrophic factor (BDNF) have failed to show a clinical benefit in ALS (W. Bradley, personal communication, 1997). However, a study of rhIGF-I in 266 patients with ALS, recently completed in North America, reported a statistically significant slowing of disease progression by 26% over 9 months, based on AALS score slopes.3

The difference in progression observed in our study is not statistically significant, and probably not clinically meaningful. The 2:1 randomization scheme resulted in a small placebo group (59 patients), which reduced the statistical power of our study. Thus, a difference similar to that observed in the North American study may have escaped detection. It should be noted that the primary efficacy variables were slightly different in the two trials, and that the LOCF analysis used in the European study has limitations. The failure to reproduce the North American result is not caused by differences in pharmacokinetics because serum trough concentrations of rhIGF-I were similar in both studies.

As reported in clinical trials in several diseases,10 we found rhIGF-I to be well tolerated. The higher mortality rate observed in the rhIGF-I group was not statistically significant, and was not observed in the North American study. A risk factor analysis showed a randomization imbalance with patients having poorer prognostic factors (age and FVC) assigned to the rhIGF-I group. After appropriate correction for this imbalance is made, the difference in survival is no longer present.

Thus, the European study does not show a beneficial effect of rhIGF-I on the progression of ALS. Analysis of the pooled data from the North American and European trials is in progress. Such information may be helpful in designing future prospective studies of rhIGF-I in ALS.

Acknowledgment

The authors thank all the patients and their families for their participation in this study.

Appendix

Centers and members of the European ALS/IGF-I Study Group: Department of Neurology, University of Munich, Germany: G.D. Borasio, R. Dax, C. Padovan, M. Wasner, A. Winkler; Department of Neurology, University of Leuven, Belgium: W. Robberecht, P. Tilkin; Department of Clinical Neurosciences, Institutes of Psychiatry and King's College School of Medicine and Dentistry, London, UK: P.N. Leigh, A. Al-Chalabi, T. Barby; Laboratory of Experimental Neurology, Academic Medical Center, Amsterdam, the Netherlands: J.M.B.V. de Jong, P.E. Vos; Department of Neurology B, University Medical Center, Angers, France: J. Emile, M. Maugin, A. Vieillart; Department of Neurology, University of Bonn, Germany: F. Jerusalem†, V. Güldenberg, C. Pohl, F. Ries; The Neuromuscular Unit, Charing Cross Hospital, London, UK: R.J. Guiloff, D. Bullingham, P. Newman, N. Nikhar; Department of Neurology, University of Milan, I.R.C.C.S. Ospedale Maggiore, Italy: V. Silani, N. Meucci, E. Nobile-Orazio, A. Sampietro, E. Vicini; Division of Neuromuscular Diseases, University of Utrecht, the Netherlands: J.H.J. Wokke, G. Valk, P.E. Vos; Cephalon, Inc., West Chester, Pennsylvania, USA: T. Dobbins, S. Hardiman, K. Ingalls.

Note. Readers can obtain 9 pages of supplementary material from the National Auxiliary Publications Service, 248 Hempstead Turnpike, West Hempstead, NY 11552. Request document no. 05470. Remit with your order (not under separate cover), in US funds only, $15.00 for photocopies or $5.00 for microfiche. Outside the United States and Canada, add postage of $4.50 for the first 20 pages and $1.00 for each 10 pages of material thereafter, or$1.75 for the first microfiche and $1.00 for each fiche thereafter. There is a $25.00 invoicing charge on all orders filled before payment.

Footnotes

  • Supported by Cephalon, Inc., and Chiron, Inc. The investigators received no financial incentives such as equity interest, patent rights, or corporate affiliation. Compensation was provided only for the cost of the study and for partial reimbursement of investigator time in carrying out the trial.

    Deceased.

    See the appendix for a list of the participants and their institutions.

    Presented in part at the 6th International Symposium of ALS/MND, Dublin, Ireland, November 1995.

    Received September 9, 1997. Accepted in final form March 10, 1998.

References

  1. 1.↵
    Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorder. Exp Neurol 1993;124:73-88.
    OpenUrl
  2. 2.↵
    Festoff BW, Yang SX, Stong D. Strategies for the use of recombinant human growth hormone and insulin-like growth factor I in amyotrophic lateral sclerosis. In: Blackman MR, Harman SM, Roth J, Shapiro JR, eds. Growth hormone releasing hormone, growth hormone and IGF-I: basic and clinical advances. New York: Springer; 1995:110-128.
  3. 3.↵
    Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor I (rhIGF-I) on the progression of amyotrophic lateral sclerosis. A placebo-controlled study. Neurology 1997;49:1621-1630.
    OpenUrlFREE Full Text
  4. 4.↵
    Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
    OpenUrl
  5. 5.↵
    Bergner M, Bobbit RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
    OpenUrlPubMed
  6. 6.↵
    Contreras PC, Steffler C, Yu E, Callison K, Stong D, Vaught JL. Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice. J Pharmacol Exp Ther 1995;274:1443-1449.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
    OpenUrl
  8. 8.↵
    Lotz B, Brooks B, Sanjak M, et al. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neutrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-1249.
    OpenUrlFREE Full Text
  9. 9.
    Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-260.
    OpenUrl
  10. 10.↵
    Froesch ER, Hussain MA, Schmid C, Zapf J. Insulin-like growth factor I: physiology, metabolic effects and clinical use. Diabetes Metab Rev 1996;12:195-215.
    OpenUrlCrossRefPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Acknowledgment
    • Appendix
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise